- The consistent use of Mexidol® from a solution to tablets, which is actualized in specialized large randomized clinical studies (RCTs) 5, 7 allows us to recommend the use of this scheme for the complete disclosure of the therapeutic potential of the drug Mexidol®.
How to apply Mexidol®
Instructions for use of the drug Mexidol: treatment regimens
Mexidol® is effectively used in both adults and children from 6 years old. In the drop -down list below
you can choose the readings, and you will be shown the recommended scheme of therapy.
Indications for use of Mexidol: tablets, solution for intramuscular administration (injections)
The presence of injection and tablet dosage forms of Mexidol® allows for consistent therapy, and a wide range of doses - to apply an individual approach to each patient, revealing the maximum therapeutic potential of the drug.
Recommended
standard for therapy 5, 7
standard for therapy 5, 7
- Children's therapy
Forms of release
2 ml No. 10
5 ml No. 5
10 ml No. 5
Mexidol® solution for Iv
and iv in introduction 50 mg/ml
and iv in introduction 50 mg/ml
1 ml contains 50 mg of the active substance
Indications 1
- acute cerebral circulation disorders;
- cerebral infarction (ischemic stroke);
- traumatic brain injury, consequences of traumatic brain injury;
- dyscirculatory encephalopathy;
- Chronic cerebral ischemia;
- Vegetative dystonia syndrome;
- Mild (moderate) cognitive disorders;
- Anxiety disorders in neurotic and neurosis-like states;
- acute myocardial infarction (from the first day) as part of complex therapy;
- primary open -angle glaucoma of various stages, as part of complex therapy;
- withdrawal syndrome in alcoholism with predominance of neurosis-like and vegetative-vascular disorders;
- acute intoxication with antipsychotic drugs;
- acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.
№30
№50
Mexidol® tablets covered with a film shell 125 mg
1 tablet contains 125 mg of the active ingredient
Approved for children of 6 years of age and older
Indications 2
- Consequences of acute cerebral circulation disorders, including those after transient ischemic attacks, in the subcompensation phase as prophylactic courses;
- Mild traumatic brain injury, consequences of traumatic brain injury;
- Encephalopathies of various origin (dyscirculatory, dysmetabolic, post-traumatic, mixed);
- Vegetative dystonia syndrome;
- Mild cognitive disorders of atherosclerotic origin;
- Anxiety disorders in neurotic and neurosis-like states;
- Ischemic heart disease as part of complex therapy;
- The relief of withdrawal syndrome in alcoholism with predominant neurosis-like and vegetative-vascular disorders, post-withdrawal disorders;
- Status post acute antipsychotic intoxication;
- Asthenic conditions, as well as prevention of somatic diseases induced by extreme factors and stress;
- Exposure to extreme (stressful) factors;
- Attention deficit hyperactivity disorder (ADHD) in children, including hyperactivity, disorder of attention, and impulsiveness.
№40
Mexidol® Fortе 250 tablets covered with
250 mg
250 mg
in 1 tablet 250 mg of active substance
Indications 3
- consequences of acute cerebrovascular accident, including after transient ischemic attacks, in the subcompensation phase as preventive courses;
- Mild traumatic brain injury, consequences of traumatic brain injury;
- Encephalopathies of various origin (dyscirculatory, dysmetabolic, post-traumatic, mixed);
- Vegetative dystonia syndrome;
- Mild cognitive disorders of atherosclerotic origin;
- Anxiety disorders in neurotic and neurosis-like states;
- Ischemic heart disease as part of complex therapy;
- The relief of withdrawal syndrome in alcoholism with predominant neurosis-like and vegetative-vascular disorders, post-withdrawal disorders;
- Status post acute antipsychotic intoxication;
- Asthenic conditions, as well as prevention of somatic diseases induced by extreme factors and stress;
- The exposure to extreme (stressful) factors.
Mexidol® is available in the following pharmacies:
Where to buy
You can order right now. Click on the logo of the Internet pharmacy, and you will be redirected to the order page*
*When ordering, a request to take into account that the product is a drug for prescription.
Where to buy
List of literature
- General characteristics of the drug Mexidol® 50 mg/ml, a solution for intravenous and intramuscular administration of LP-№ 000107 RG-RUR dated 12.12.2023
- General characteristics of the drug Mexidol® 125 mg, tablets coated with the film shell of LP-№ 000086 RG-RUR dated 08.02.2023
- General characteristics of the drug Mexidol® Fort 250, 250 mg, tablets covered with the film shell of lp-№ 000066 RG-RUR dated 12/19/2023
- Zavadenko N. N., Suvorinova N. Yu., Batysheva T. T., Bykova O. V., Platonova A.N., Gainetdinova D. D., Levitina E.V., Machin V.V., Vakula and Vakula and Vakula and . Journal of neurology and psychiatry named after S. S. Korsakova. 2022; 122 (4): 75–86.
- Stakhovskaya L.V., Shamalov N. A. The results of a randomized double-cententer placebo-controlled multicenter-controlled in parallel groups of the efficiency and safety of Mexidol with prolonged sequential therapy in patients in the acute and early recovery periods of the half-step ischemic stroke (Epica) // Journal of Neurology and the Journal of Neurology Psychiatry named after S. S. Korsakova, No. 3, 2017, Issue 2 “Stroke”, pp. 55–65.
- Strelnikova I.A. with co -author. The effectiveness and safety of the drug Mexidol Fort 250 in the framework of prolonged consistent therapy in patients with ischemic stroke in the carotid system // Journal of Neurology and Psychiatry named after S. S. Korsakova. 2020; 120 (3 outp. 2): 54-59.
- Fedin A.I., Zakharov V.V., Tanashyan M. M., Chukanova E.I., Majidova E. N., Shchepanevich L. A., Ostroumova O. D. The results of an international multicenter randomized bouncer-controlled Studies of assessing the effectiveness and safety of consistent therapy of patients with chronic brain ischemia drugs Mexidol and Mexidol Forte 250 (study of Memo). Journal of neurology and psychiatry named after S. S. Korsakova. 2021; 121 (11): 7-16.
- Bogolepova A. N. Features of pharmacotherapy of vascular cognitive disorders in elderly people. Journal of neurology and psychiatry named after S. S. Korsakova. 2023; 123 (9): 15–20.
- Zakharov V.V., Tkacheva O. N., Mkhitaryan E.A., Fedin A. I. The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia and cognitive disorders (the results of the subanalysis of the international multicenth-centered double blind and controlled study Memo). Journal of neurology and psychiatry named after S. S. Korsakova. 2022; 122 (11 outp. 2): 1–8.
- Chukanova E.I., Chukanova A.S. The effectiveness and safety of the drug Mexidol Forte 250 in the framework of consistent therapy in patients with chronic brain ischemia. Journal of neurology and psychiatry named after S. S. Korsakova. 2019; 119 (9): 39-45.
- Abramenko Yu. V. The results of the sequential use of Mexidol and Mexidol Forte 250 in patients with chronic brain ischemia. Journal of neurology and psychiatry named after S. S. Korsakova. 2020; 120 (3 outp. 2): 60-65.
- Egorov E.A., Gvetadze A. A, Davydova N. G. Antioxidant drug in neuroprotective therapy for glaucoma // Bulletin of ophthalmology, No. 2, 2013, p. 67–69.
- Loskutov I.A., Andryukhina O.M., Kovrizhkina A.A. The use of Mexidol in therapy of primary open -angle glaucoma. Effective pharmacotherapy. 2022; 18 (11): 52–56.
- Duma S. N. The possibilities of antioxidant therapy for asthenia and cognitive deficiency in elderly patients with chronic brain ischemia // Therapeutic archive, No. 12, 2013, pp. 100–105.
THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.
Source of photos and images Shutterstock.com